ClinicalTrials.gg
CompletedNCT02487030Updated Nov 16, 2018Results posted

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection

A Phase 3 interventional study of LDV/SOF and RBV in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 4 sites in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 174 studies testing ribavirin in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. Ribavirin · Hepatitis C.

Enrollment
33rd of 174
255 · median 78
Started
2015
with 19 others
Phase 3
56 of 174
none open now
Registered
149th of 174
by date
Lead sponsor
15 of 174
Gilead Sciences

Among the 174 studies testing ribavirin in Hepatitis C, this one is the 33rd largest by enrollment, is one of 20 that started in 2015, is one of 56 in phase 3, and was the 149th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 174 studies testing ribavirin in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About ribavirin

Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 174 studies testing ribavirin in Hepatitis C as a file.
02

Study summary

The primary objective of this study was to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) with or without ribavirin (RBV) in Egyptian adults with chronic genotype 4 hepatitis C virus (HCV) infection.

03

Conditions studied

  • Hepatitis C Virus Infection

Keywords

  • HCV genotype 4 (GT-4)
  • HCV
  • Sustained Virologic Response
  • Direct Acting Antiviral
  • Combination Therapy
  • GS-7977
  • GS-5885
  • Ribavirin
  • Sofosbuvir
  • ledipasvir
  • Hepatitis C
  • Hepatitis C, Chronic
  • Liver Diseases
  • Virus Diseases
  • Antiviral Agents
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Willing and able to provide written
  • Chronic infection (≥ 6 months) documented by medical history or liver
  • HCV genotype 4 at screening
  • HCV treatment naive or prior participation in this study or study GS-US-334-0138 (Cohorts 1 and 2 only)
  • Cohort 3 only: HCV treatment-experienced (previously received therapy for HCV infection with an interferon (IFN)-containing regimen, with or without RBV and/or an HCV NS3/NS4A protease inhibitor (PI)
  • (BMI) ≥ 18 kg/m\^2
  • Screening laboratory values within defined thresholds
  • Use of effective protocol-approved methods

Key Exclusion Criteria:

  • History of clinically-significant illness or any other major medical disorder that may interfere with treatment, assessment or compliance with the protocol
  • Infection with virus (HBV) or (HIV)
  • Pregnant or nursing females or male with pregnant female partner
  • Clinically-relevant drug or alcohol abuse within 12 months of screening

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    LDV/SOF 8 wk TN (Cohort 1, Group 1)

    LDV/SOF for 8 weeks (treatment-naive (TN))

    Drug: LDV/SOF

  • Experimental
    LDV/SOF+RBV 8 wk TN (Cohort 1, Group 2)

    LDV/SOF+RBV for 8 weeks (treatment-naive)

    Drug: LDV/SOF · Drug: RBV

  • Experimental
    LDV/SOF 12 wk TN (Cohort 1, Group 3)

    LDV/SOF for 12 weeks (treatment-naive)

    Drug: LDV/SOF

  • Experimental
    LDV/SOF+RBV 12 wk TN (Cohort 1, Group 4)

    LDV/SOF+RBV for 12 weeks (treatment-naive)

    Drug: LDV/SOF · Drug: RBV

  • Experimental
    LDV/SOF+RBV 12 wk TE (Cohort 2)

    Treatment-experienced (TE) participants who completed treatment in Gilead sponsored study GS-US-334-0138 or in Cohort 1 of this study and did not achieve SVR12 will receive LDV/SOF+RBV for 12 weeks.

    Drug: LDV/SOF · Drug: RBV

  • Experimental
    LDV/SOF 12 wk TE (Cohort 3, Group 1)

    LDV/SOF for 12 weeks (treatment-experienced)

    Drug: LDV/SOF

  • Experimental
    LDV/SOF+RBV 12 wk TE (Cohort 3, Group 2)

    LDV/SOF+RBV for 12 weeks (treatment-experienced)

    Drug: LDV/SOF · Drug: RBV

Interventions

  • DrugLDV/SOF

    90/400 mg FDC tablet administered orally once daily

    Also known as: Harvoni®, GS-5885/GS-7977

  • DrugRBV

    Tablets administered orally in a divided daily dose based on weight (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)

    SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.

    Time frame: Posttreatment Week 12

  2. Percentage of Participants Who Discontinued LDV/SOF Drug Due to an Adverse Event (AE)

    Time frame: 12 weeks

Secondary outcomes

  1. Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)

    SVR4 and SVR24 were defined as HCV RNA \< LLOQ 4 and 24 weeks after the last dose of study drug, respectively.

    Time frame: Posttreatment Weeks 4 and 24

  2. Percentage of Participants With Overall Virologic Failure

    Virologic failure was defined as * On-treatment virologic failure * confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ, while on treatment (ie, breakthrough), * confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment (ie, rebound), * HCV RNA persistently ≥ LLOQ through 8 weeks of treatment (ie, nonresponse) * Relapse * HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement

    Time frame: Up to Posttreatment Week 24

07

Results

Posted Dec 14, 2017

Participant flow

Participants were enrolled in 4 sites in Egypt. The first participant was screened on 07 September 2015 and the last study visit was on 04 February 2017.

Participant flow — Overall Study
MilestoneLDV/SOF 8 wk TN (Cohort 1, Group 1)LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2)LDV/SOF 12 wk TN (Cohort 1, Group 3)LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4)LDV/SOF 12 wk TE (Cohort 3, Group 1)LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2)LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2)
Started43424342363811
Completed41384140343711
Not completed2422210
Withdrew: Lack of efficacy2410100
Withdrew: Lost to follow-up0011010
Withdrew: Adverse event0001000
Withdrew: Death0000100

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)

SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.

Time frame:
Posttreatment Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
percentage of participantsLDV/SOF 8 wk TN (Cohort 1, Group 1)LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2)LDV/SOF 12 wk TN (Cohort 1, Group 3)LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4)LDV/SOF 12 wk TE (Cohort 3, Group 1)LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2)LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2)
Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)95.3 (84.2 to 99.4)90.5 (77.4 to 97.3)97.7 (87.7 to 99.9)97.6 (87.4 to 99.9)94.4 (81.3 to 99.3)100.0 (90.7 to 100.0)100.0 (71.5 to 100.0)
PrimaryPercentage of Participants Who Discontinued LDV/SOF Drug Due to an Adverse Event (AE)
Time frame:
12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued LDV/SOF Drug Due to an Adverse Event (AE)
percentage of participantsLDV/SOF 8 WeeksLDV/SOF + RBV 8 WeeksLDV/SOF 12 WeeksLDV/SOF + RBV 12 Weeks
Percentage of Participants Who Discontinued LDV/SOF Drug Due to an Adverse Event (AE)0001.1
SecondaryPercentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)

SVR4 and SVR24 were defined as HCV RNA \< LLOQ 4 and 24 weeks after the last dose of study drug, respectively.

Time frame:
Posttreatment Weeks 4 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
percentage of participantsLDV/SOF 8 wk TN (Cohort 1, Group 1)LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2)LDV/SOF 12 wk TN (Cohort 1, Group 3)LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4)LDV/SOF 12 wk TE (Cohort 3, Group 1)LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2)LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2)
SVR495.3 (84.2 to 99.4)95.2 (83.8 to 99.4)97.7 (87.7 to 99.9)97.6 (87.4 to 99.9)100.0 (90.3 to 100.0)100.0 (90.7 to 100.0)100.0 (71.5 to 100.0)
SVR2495.3 (84.2 to 99.4)90.5 (77.4 to 97.3)97.7 (87.7 to 99.9)97.6 (87.4 to 99.9)94.4 (81.3 to 99.3)100.0 (90.7 to 100.0)100.0 (71.5 to 100.0)
SecondaryPercentage of Participants With Overall Virologic Failure

Virologic failure was defined as * On-treatment virologic failure * confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ, while on treatment (ie, breakthrough), * confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment (ie, rebound), * HCV RNA persistently ≥ LLOQ through 8 weeks of treatment (ie, nonresponse) * Relapse * HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement

Time frame:
Up to Posttreatment Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Virologic Failure
percentage of participantsLDV/SOF 8 wk TN (Cohort 1, Group 1)LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2)LDV/SOF 12 wk TN (Cohort 1, Group 3)LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4)LDV/SOF 12 wk TE (Cohort 3, Group 1)LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2)LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2)
Percentage of Participants With Overall Virologic Failure4.79.52.30.02.80.00.0

Adverse events

Collected over Up to 12 weeks + 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LDV/SOF 8 Weeks—0/43 (0%)11/43 (25.6%)
LDV/SOF + RBV 8 Weeks—0/42 (0%)15/42 (35.7%)
LDV/SOF 12 Weeks—0/79 (0%)23/79 (29.1%)
LDV/SOF + RBV 12 Weeks—3/91 (3.3%)41/91 (45.1%)
Most frequent serious events
Most frequent serious events
EventLDV/SOF 8 WeeksLDV/SOF + RBV 8 WeeksLDV/SOF 12 WeeksLDV/SOF + RBV 12 Weeks
Road traffic accidentInjury, poisoning and procedural complications0/430/420/792/91
Chest PainGeneral disorders0/430/420/791/91
Peripheral vascular disorderVascular disorders0/430/420/791/91
Most frequent other events
Most frequent other events
EventLDV/SOF 8 WeeksLDV/SOF + RBV 8 WeeksLDV/SOF 12 WeeksLDV/SOF + RBV 12 Weeks
HeadacheNervous system disorders4/4313/4213/7920/91
FatigueGeneral disorders4/435/428/7914/91
AnaemiaBlood and lymphatic system disorders0/432/420/797/91
ConstipationGastrointestinal disorders0/433/420/793/91
DyspepsiaGastrointestinal disorders3/431/425/796/91
BronchitisInfections and infestations3/431/423/792/91
Abdominal pain upperGastrointestinal disorders0/432/420/796/91
PyrexiaGeneral disorders1/431/421/795/91

Baseline characteristics

Safety Analysis Set: participants who were randomized or enrolled and received at least 1 dose of study drug

Age, Continuous
Age, Continuous(years)LDV/SOF 8 wk TN (Cohort 1, Group 1)LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2)LDV/SOF 12 wk TN (Cohort 1, Group 3)LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4)LDV/SOF 12 wk TE (Cohort 3, Group 1)LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2)LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2)Total
Mean53 ± 13.949 ± 12.249 ± 13.046 ± 12.149 ± 11.851 ± 10.148 ± 16.350.0 ± 12.5
Sex: Female, Male
Sex: Female, Male(Participants)LDV/SOF 8 wk TN (Cohort 1, Group 1)LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2)LDV/SOF 12 wk TN (Cohort 1, Group 3)LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4)LDV/SOF 12 wk TE (Cohort 3, Group 1)LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2)LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2)Total
Female18202120413399
Male2522222232258156
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LDV/SOF 8 wk TN (Cohort 1, Group 1)LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2)LDV/SOF 12 wk TN (Cohort 1, Group 3)LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4)LDV/SOF 12 wk TE (Cohort 3, Group 1)LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2)LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2)Total
White43424342363811255
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LDV/SOF 8 wk TN (Cohort 1, Group 1)LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2)LDV/SOF 12 wk TN (Cohort 1, Group 3)LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4)LDV/SOF 12 wk TE (Cohort 3, Group 1)LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2)LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2)Total
Not Hispanic or Latino43424342363811255
IL28b Status
IL28b Status(Participants)LDV/SOF 8 wk TN (Cohort 1, Group 1)LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2)LDV/SOF 12 wk TN (Cohort 1, Group 3)LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4)LDV/SOF 12 wk TE (Cohort 3, Group 1)LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2)LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2)Total
CC12511988053
CT2826262524218158
TT3116879347
HCV RNA
HCV RNA(log10 IU/mL))LDV/SOF 8 wk TN (Cohort 1, Group 1)LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2)LDV/SOF 12 wk TN (Cohort 1, Group 3)LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4)LDV/SOF 12 wk TE (Cohort 3, Group 1)LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2)LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2)Total
Mean6.0 ± 0.645.6 ± 0.635.7 ± 0.695.8 ± 0.665.8 ± 1.105.8 ± 1.046.2 ± 0.595.8 ± 0.79
HCV RNA Category
HCV RNA Category(Participants)LDV/SOF 8 wk TN (Cohort 1, Group 1)LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2)LDV/SOF 12 wk TN (Cohort 1, Group 3)LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4)LDV/SOF 12 wk TE (Cohort 3, Group 1)LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2)LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2)Total
< 800,000 IU/mL1726252816175134
≥ 800,000 IU/mL2616181420216121
08

Study locations

4 sites
  • Cairo, 11559, Egypt
  • Cairo, 11796, Egypt
  • Mansourah, Egypt
  • Shibin Al Kawm, Egypt
09

References and documents

Publications

  • Shiha G, Waked I, Soliman R, Abdelrazek W, Hassany M, Fouad R, et al. Ledipasvir/sofosbuvir for 8 or 12 weeks with or without ribavirin in HCV genotype 4 patients in Egypt. [Abstract OP158]. Asian Pacific Association for the Study of the Liver (APASL); 2017 15-19 February; Shanghai, China
  • Shiha G, Esmat G, Hassany M, Soliman R, Elbasiony M, Fouad R, Elsharkawy A, Hammad R, Abdel-Razek W, Zakareya T, Kersey K, Massetto B, Osinusi A, Lu S, Brainard DM, McHutchison JG, Waked I, Doss W. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. Gut. 2019 Apr;68(4):721-728. doi: 10.1136/gutjnl-2017-315906. Epub 2018 Apr 17. PubMed 29666174 ↗

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Nov 2016, 14 months.

Results were first posted in Dec 2017, 1 year 1 month after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Hepatitis C, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 18. This study's 14 months is close to that.

Counting every sponsor, half of 90 studies reached it within 14 months; a quarter within 10 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2015
First posted
Jul 1, 2015
StartActual
Sep 7, 2015
Primary completionActual
Nov 11, 2016
CompletionActual
Feb 4, 2017
Results first posted
Dec 14, 2017
Last update
Nov 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02487030
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jul 1, 2015
Start date
Sep 7, 2015
Primary completion
Nov 11, 2016
Completion
Feb 4, 2017
Results posted
Dec 14, 2017
Last update
Nov 16, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribavirin

Start the discussion